MedPath

Etomidate/Propofol Mixture or Propofol Monotherapy Use in Patients Undergoing General Anesthesia

Not Applicable
Conditions
Etomidate is Mixed With Propofol
Interventions
Registration Number
NCT03855267
Lead Sponsor
Guolin Wang
Brief Summary

The purpose of this study was to investigate the effects of different proportions of etomidate/propofol mixture and propofol alone intravenous anesthesia on intraoperative and postoperative physiological indicators and complications, and to find out the optimal use ratio of E/P mixture.

Detailed Description

Propofol is one of the most commonly used intravenous anesthesia drugs clinically, the pharmacokinetic characteristics makes it very suitable for total intravenous anesthesia( TIVA), etomidate belongs to intravenous anesthesia with propofol, is a derivative of the imidazoles, its calm performance is strong, work quickly, no obvious respiratory depression, had little effects on the cardiovascular system, which, therefore, to protect the cardiovascular, maintain hemodynamic stability has a certain advantage. Our previous project showed that propofol and etomidate combined application can maintain stable hemodynamics in patients with better, reduce the occurrence of adverse reactions, can be used within 3 h of surgery anesthesia.The purpose of this study is to use propofol or etomidate/propofol mixture in combination with BIS monitoring to perform general anesthesia maintenance for patients, in order to ensure the appropriate depth of anesthesia, better maintain the hemodynamic stability of patients, reduce adverse reactions, and find the appropriate E/P mixture of the best proportion and dose.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  1. Patients undergoing elective general anesthesia surgery in 3h;
  2. American Society of Anesthesiologists gradesⅠ~III;
  3. Aged 18 to 65 years, Body Mass Index 18.5 ~ 29.9kg / m2;
  4. Hemoglobin 100 ~ 125g / L.
  5. In line with the ethics, the patients volunteered to take the test and signed the informed consent
Exclusion Criteria
  1. Identify or suspect abuse or chronic use of narcotic sedatives and analgesics;
  2. Heart, or liver, or lung, or kidney dysfunction;
  3. Body mass index> 30kg / m2; or <18.5kg / m2
  4. Speech, hearing or mental disorders;
  5. severe diabetes, hyperkalemia ;
  6. participate in other drug clinical researches in four weeks;
  7. Poor compliance, can not complete clinical research by research program.
  8. Any cerebrovascular accident occurred within 3 months, such as stroke, TIA, etc
  9. Unstable angina and myocardial infarction occurred within 3 months;
  10. Having contraindications or allergies to experimental drugs and other narcotic drugs;
  11. Mental illness, hyperkalemia.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
GroupBPropofol 20 mg/ml , etomidate 2 mg/mlEP1:3, that is, 10ml etomidate was mixed with 30ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
Group APropofol 20 MG/MLPropofol 20 mg/ml, recommended anesthesia induction dose of 0.1\~0.125 ml/kg, anesthesia maintenance pump speed of 0.2\~0.5ml/kg/h. keep bispectral index within 40 # 60
Group CPropofol 20 mg/ml , etomidate 2 mg/mlEP1:1, that is, 20ml etomidate was mixed with 20ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
Group DPropofol 20 mg/ml , etomidate 2 mg/mlEP3:1, that is, 30ml etomidate was mixed with 10ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
Primary Outcome Measures
NameTimeMethod
blood pressureintraoperative

the blood pressure is recorded (mmHg)

heart rateintraoperative

the heart rate is recorded(bpm)

Secondary Outcome Measures
NameTimeMethod
Perioperative complicationsintraoperative

the incidence of injection pain #nausea and vomit#intraoperative awareness and postoperative agitation.

Trial Locations

Locations (1)

Zicheng Wang

🇨🇳

Tianjin, Tianjin, China

Zicheng Wang
🇨🇳Tianjin, Tianjin, China
Zicheng wang, MM
Contact
13821112922
527640484@qq.com
© Copyright 2025. All Rights Reserved by MedPath